Cargando…

B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease

Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher’s interest in the treatment of solid tumors. Sarcomas are a het...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Rui Caetano, Gama, João, Casanova, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501895/
https://www.ncbi.nlm.nih.gov/pubmed/37720343
http://dx.doi.org/10.37349/etat.2023.00154
_version_ 1785106204720103424
author Oliveira, Rui Caetano
Gama, João
Casanova, José
author_facet Oliveira, Rui Caetano
Gama, João
Casanova, José
author_sort Oliveira, Rui Caetano
collection PubMed
description Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher’s interest in the treatment of solid tumors. Sarcomas are a heterogeneous group of diseases, comprising several entities, with high morbidity and mortality and with few specific therapies available. The treatment for sarcomas is based on platinum regimens, with variable results and poor outcomes, especially in advanced lesions. The high number of different sarcoma entities makes treatment standardization as well as the performance of clinical trials difficult. The use of Bcl-2 family members modifiers has revealed promising results in in vitro and in vivo models and may be a valid option, especially when used in combination with chemotherapy. In this article, a revision of these results and possibilities for the use of Bcl-2 family members inhibitors in sarcomas was performed.
format Online
Article
Text
id pubmed-10501895
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Open Exploration Publishing
record_format MEDLINE/PubMed
spelling pubmed-105018952023-09-16 B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease Oliveira, Rui Caetano Gama, João Casanova, José Explor Target Antitumor Ther Review Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regulation and, has captured the researcher’s interest in the treatment of solid tumors. Sarcomas are a heterogeneous group of diseases, comprising several entities, with high morbidity and mortality and with few specific therapies available. The treatment for sarcomas is based on platinum regimens, with variable results and poor outcomes, especially in advanced lesions. The high number of different sarcoma entities makes treatment standardization as well as the performance of clinical trials difficult. The use of Bcl-2 family members modifiers has revealed promising results in in vitro and in vivo models and may be a valid option, especially when used in combination with chemotherapy. In this article, a revision of these results and possibilities for the use of Bcl-2 family members inhibitors in sarcomas was performed. Open Exploration Publishing 2023 2023-08-24 /pmc/articles/PMC10501895/ /pubmed/37720343 http://dx.doi.org/10.37349/etat.2023.00154 Text en © The Author(s) 2023. https://creativecommons.org/licenses/by/4.0/This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Oliveira, Rui Caetano
Gama, João
Casanova, José
B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
title B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
title_full B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
title_fullStr B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
title_full_unstemmed B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
title_short B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
title_sort b-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501895/
https://www.ncbi.nlm.nih.gov/pubmed/37720343
http://dx.doi.org/10.37349/etat.2023.00154
work_keys_str_mv AT oliveiraruicaetano bcelllymphoma2familymembersandsarcomasapromisingtargetinaheterogeneousdisease
AT gamajoao bcelllymphoma2familymembersandsarcomasapromisingtargetinaheterogeneousdisease
AT casanovajose bcelllymphoma2familymembersandsarcomasapromisingtargetinaheterogeneousdisease